Therapy of hepatocellular cancer with iodine-131-Lipiodol. State of the art

Romanian Journal of Gastroenterology

Volumn 13, Issue 2, 2004, Pages 119-124

  Risse, Jörn H ^a   Menzel, Christian ^b   Grünwald, Frank ^b   Strunk, Holger ^c   Biersack, Hans Jürgen ^c   Palmedo, Holger ^c  

^a Radiol and Nucl Medicine Institute   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer therapy; Hepatocellular cancer; Iodine 131 Lipiodol

Indexed keywords

CISPLATIN; CORTICOSTEROID; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM PERCHLORATE; TAMOXIFEN;

ARTIFICIAL EMBOLISM; DYSPNEA; FEVER; HUMAN; INJECTION PAIN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG DISEASE; PNEUMONIA; PORTAL VEIN THROMBOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; HUMANS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS;

EID: 3142523528     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenger MH, Scharschmidt BF, eds.: Sleisenger & Fordtran's gastrointestinal and liver disease: pathology/diagnosis/management. 6th ed. Philadelphia: W.B. Saunders, 1998; 1364-1387.
2. Becker N, Warendorf J. Krebsatlas der Bundesrepublik Deutschland 1981-1990. 3 ed. Berlin: Springer, 1998.
3. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351: 214-215.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
5. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-4972.
6. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143.
7. Caselmann WH, Blum HE, Fleig WE et al. Leitlinien der deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zur Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 1999; 37: 353-365.
8. Di Bisceglie AH. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (Suppl. 1): 34S-38S.
9. Rabe C, Pilz T, Klostermann et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma first treated between 1997 and 1999 at a German tertiary care medical center. World J Gastroenterol 2001; 7: 208-215.
10. Sterneck M. Ätiologie des hepatozellulären Karzinoms. Internist 2000; 41: 185-190.
11. de Baere T, Zhang X, Aubert B et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996; 201:731-735.
12. Raoul JL, Bourguet P, Bretagne JF et al. Hepatic artery injection of I-I31-labeled lipiodol. Part 1: Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541-545.
13. Ackerman N, Makohou S. The effects of cooling, freeying and thawing on vascular permeability and perfusion in experimental liver metastases. Surg Gynecol Obstet 1981; 152:262-267.
14. Bhattacharya S, Dhillon AP, Winslet MC et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 1996; 73:877-881.
15. Chou FI, Fang KC, Chung C et al. Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 1995; 22:379-386.
16. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6:559-593.
17. Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors: an experimental investigation in several animal species. Acta Radiol 1996; 37 (Suppl):6-25.
18. Miller DL, O'Leary TJ, Girton M. Distribution of iodized oil within the liver after hepatic arterial injection. Radiology 1987; 162:849-852.
19. Valls C, Figueras J, Jaurrieta E et al. Hepatocellular carcinoma: Iodized oil CT TNM classification. Am J Roentgenol 1996; 167: 477-481.
20. Vogl TJ, Hammerstingl R, Mack M et al.: Diagnostik und Interventionen bei malignen Lebertumoren. Med Welt 1998; 49: 511-518.
21. Vogl TJ, Trapp M, Schroeder H et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success - results from a liver transplantation center. Radiology 2000;214:349-357.
22. Chung JN, Park JH, Han JK et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: 33-40.
23. de Baere T, Dufaux J, Roche A et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 1995; 194:165-170.
24. Raoul JL, Guyader D, Bretagne JF et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-1787.
25. Bell E, Grünwald F. Radiojodtherapie bei benignen und malignen Schilddrüsenerkrankungen. Berlin, Heidelberg, New York: Springer, 1999.
26. Biersack HJ, Hotze AL. Radionuklid-Therapie. Dt Ärztebl 1993; 90: A1- 1724-1729.
27. Bretagne JF, Raoul JL, Bourguet P et al. Hepatic artery injection of I-131-labeled Lipiodol. Part 2: Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 547-550.
28. Nakajo M, Kobayashi H, Shimabukuro K et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29: 1066-1077.
29. Yoo HS, Park CH, Suh JH et al. Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. Cancer Chemother Pharmacol 1989;23 (Suppl.):S54-S58.
30. Madsen MT, Park CH, Thakur ML. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 1988; 29:1038-1044.
31. Risse JH, Grünwald F, Ponath C, Biersack HJ. Radiation protection in I-131-Lipiodol therapy in liver neoplasms. In: Bergmann H, Köhn H, Sinzinger H, eds.: Radioactive isotopes in clinical medicine and research XXIII. Basel, Boston, Berlin: Birkhäuser, 1999; 297-302.
32. Risse JH, Ponath C, Palmedo H, Menzel C, Grünwald F, Biersack HJ. Radiation exposure and radiation protection of the physician in I-131-Lipiodol therapy of liver tumours. Eur J Nucl Med 2001; 28: 914-918
33. Risse JH, Grünwald F, Strunk H, Bultmann T, Biersack HJ. 1-131-Lipiodol therapy in liver neoplasms. In: Bergmann H, Köhn H, Sinzinger H, eds.: Radioactive isotopes in clinical medicine and research XXIII. Basel, Boston, Berlin: Birkhäuser, 1999; 65-70.
34. Risse JH, Grünwald F, Kersjes W et al. Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radio Pharm 2000; 15: 65-70.
35. Risse JH, Grünwald F, Strunk H et al. 18-FDG-PET and 3-phase helical liver CT in intraarterial therapy with I-131-Lipiodol in primary liver cancer. Eur J Nucl Med 1998; 25: 1032.
36. Kobayashi H, Nakajo M, Shimabukuro K et al. [Possibility of radiotherapy of hepatic cancer by transcatheter arterial embolization with radioactive Lipiodol]. Nippon Acta Radiol 1984;44:96-98.
37. Kobayashi H, Nakajo M, Yano T, Shimabukuro K, Shinohara S. Transcatheter internal radiotherapy of hepatoma using radioactive iodized oil (I-131 Lipiodol). Nippon Acta RadioI Radiol 1985;45:1176-1178.
38. Risse JH, Grünwald F, Strunk H, Kleinschmidt R, Bender H, Biersack HJ. I-131-Lipiodol therapy in liver neoplasms. Hybridoma 1999; 18: 83-85.
39. Kobayashi H, Hidaka H, Kajiya Y et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn 1986; 27: 139-147.
40. de Baere T, Taourel P, Tubiana JM et al. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 1999;212:665-668.
41. Leung WT, Lau WY, Ho S et al. Selective internal radiation therapy with intra-arterial Iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35: 1313-1318.
42. Raoul JL, Guyader D, Bretagne JF et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131 I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
43. Lui WY, Liu RS, Chiang JH et al. Report of a pilot study of intraarterial injection of I-131 lipiodol for the treatment of hepatoma. Chin Med J (Taipei) 1990;46:125-133.
44. Raoul JL, Bretagne JF, Caucanas JP. Internal radiation therapy for hepatocellular carcinoma. Cancer 1992; 69:346-352.
45. Yoo HS, Lee JT, Kim KW et al. Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine-131-labeled iodiyed oil. Cancer 1991; 68: 1878-1884.
46. Monsieurs MA, Bacher K, Brans B, et al. Patient dosimetry for 131-I-lipiodol therapy. Eur J Nucl Med Mol Imaging 2003; 30: 554-561.
47. Lau WY, Leung TW, Ho SK et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801.
48. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-Lipiodol chemotherapy versus 131 iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76:2202-2210.
49. Hatanaka Y, Yamashita Y, Takahashi M et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995; 195:747-752.
50. Bremer C, Allkemper T, Menzel J et al. Preliminary clinical experience with laser-induced interstitial thermotherapy in patients with hepatocellular carcinoma. J Magn Reson Imaging 1998; 8: 235-239.
51. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-108.
52. Livraghi T, Goldberg SN, Lazzaroni S et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761-768.
53. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Sotbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-661.
54. Allgaier HP, Deibert P, Olschewski M et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer 1998;79:601-605.
55. Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum 1979;22:371-375.